Results 71 to 80 of about 2,224,846 (160)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, Volume 20, Issue 10, Page 2424-2448, October 2026.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2‐Negative Breast Cancer: A Real‐World Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Circulating tumor DNA (ctDNA) is a promising biomarker for disease monitoring, yet evidence of its clinical utility in routine care remains limited. We evaluated the utility of serial ctDNA monitoring using digital PCR (ddPCR) for detecting acquired resistance (AR) and monitoring response in metastatic non‐small cell lung cancer (NSCLC) and ...
Franciele Hinterholz Knebel, Maurício Fernando Silva Almeida Ribeiro, Rudinei Diogo Marques Linck, Isabela Flauzino Ferreira, Cibele Masotti, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, Leandro Jonata Carvalho Oliveira, Daniele Coelho Duarte, Paula Fontes Asprino, Ernande Xavier dos Santos, Elisângela Monteiro Coser, Dimitrios Kleftogiannis, Louise J. Barber, Marco Gerlinger, João Victor Machado Alessi, Andrea Kazumi Shimada, Fernando Costa Santini, Ciro Eduardo de Souza, Olavo Feher, Gilberto de Castro Junior, Frederico Perego Costa, Max Senna Mano, Artur Katz, Anamaria Aranha Camargo, Fabiana Bettoni   +26 more
wiley   +1 more source

Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors

BMC Cancer, 2012
Background Epidermal growth factor receptor (EGFR) signaling plays an important role in non-small cell lung cancer (NSCLC) and therapeutics targeted against EGFR have been effective in treating a subset of patients bearing somatic EFGR mutations. However,
Ghosh Gargi, Lian Xiaojun, Kron Stephen J, Palecek Sean P   +3 more
doaj   +1 more source

Glutamine Metabolism in Health and Diseases

MedComm, Volume 7, Issue 10, October 2026.
Glutamine metabolism acts as a metabolic hub connecting cellular stress adaptation, immune regulation, and disease development. Through regulating energy production, biosynthesis, redox balance, and nitrogen metabolism, glutamine supports cellular homeostasis under physiological and pathological conditions.
Yi Ding, Fan Tong, Jing Zeng, Chun‐Ping Cui   +3 more
wiley   +1 more source

Targeting ferroptosis pathway to overcome erlotinib resistance

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. For advanced NSCLC, targeted therapies are often recommended to improve prognosis by acting on specific genetic mutations.
Hou, Tianxu
core   +1 more source

Receptor‐Targeted Niosomal Nanocarriers: Advances, Challenges, and Opportunities in Natural Compound Delivery for Cancer Therapy

Nano Select, Volume 7, Issue 10, October 2026.
Surface‐modified niosomes are introduced as multifunctional nanoparticles for precision tumor treatment that combine hydrophilic and lipophilic drug encapsulation with ligand‐based targeting via antibodies, peptides, transferrin, and folic acid. This modification leads to increased tumor selectivity, facilitates cell entry, and enables enhanced ...
Narges Sahraei, Aryan M. Faraj, Faezeh Molaei, Abolfazl Barzegar   +3 more
wiley   +1 more source

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

eLife, 2015
Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor regression but it is invariably followed by drug resistance. In characterizing early transcriptional changes following drug treatment of mutant EGFR-addicted cells, we ...
S Michael Rothenberg, Kyle Concannon, Sarah Cullen, Gaylor Boulay, Alexa B Turke, Anthony C Faber, Elizabeth L Lockerman, Miguel N Rivera, Jeffrey A Engelman, Shyamala Maheswaran, Daniel A Haber   +10 more
doaj   +1 more source

Genotype‐directed therapy for non–small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 10, Page 2089-2096, October 2026.
In this retrospective case series from a single database of pregnant women with cancer, seven were diagnosed with non‐small cell lung cancer (NSCLC). Chemotherapy and in some cases also biomarker‐directed therapy during pregnancy were associated with disease control allowing delivery closer to term and resulting in improved maternal outcomes compared ...
Reed Firestone, John Gaughan, Elyce Cardonick   +2 more
wiley   +1 more source

JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation [PDF]

, 2012
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non-small cell lung cancer with activating EGFR mutations.
Tanimoto, Mitsune, Takeda, Hiromasa, Eiki Ichihara, Nobuaki Ochi, Takashi Ninomiya, Nagio Takigawa, Yasugi, Masayuki, Takata, Saburo, Harada, Daijiro, Mitsune Tanimoto, Daijiro Harada, Kiura, Katsuyuki, Masayuki Yasugi, Toshio Kubo, Saburo Takata, Kadoaki Ohashi, Katsuyuki Kiura, Ninomiya, Takashi, Ichihara, Eiki, Ochi, Nobuaki, Hiromasa Takeda, Takigawa, Nagio, Kubo, Toshio, Ohashi, Kadoaki   +23 more
core   +1 more source

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source